AstraZeneca Pharma India Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Revenue	22,756	17,163	12,955	10,030	8,056
Other Revenue	284.9	-	-	-	-
Revenue	23,041	17,163	12,955	10,030	8,056
Revenue Growth (YoY)	34.25%	32.48%	29.17%	24.50%	-0.98%
Cost of Revenue	13,805	9,688	6,008	3,660	3,169
Gross Profit	9,235	7,475	6,947	6,370	4,887
Selling, General & Admin	3,804	2,590	2,419	2,591	2,303
Other Operating Expenses	2,355	2,331	2,610	2,111	1,679
Operating Expenses	6,616	5,327	5,233	4,881	4,193
Operating Income	2,619	2,148	1,714	1,489	693.6
Interest Expense	-44.9	-14.6	-12	-6.3	-9.5
Interest & Investment Income	-	315.6	325.7	231.2	114.8
Currency Exchange Gain (Loss)	-	-3.7	-5	2.8	-1.3
Other Non Operating Income (Expenses)	-	87.5	20.2	2.1	4.6
EBT Excluding Unusual Items	2,575	2,533	2,043	1,718	802.2
Merger & Restructuring Charges	-	-	-	-211.3	-
Gain (Loss) on Sale of Assets	-	3.2	0.3	24.9	28.2
Asset Writedown	-	-4.6	-12.4	-	-
Other Unusual Items	-52.5	-967.9	164.3	-191	-
Pretax Income	2,522	1,564	2,195	1,341	830.4
Income Tax Expense	646.8	406.2	580.3	348.1	214.4
Net Income	1,875	1,157	1,615	992.9	616
Net Income to Common	1,875	1,157	1,615	992.9	616
Net Income Growth	62.02%	-28.34%	62.67%	61.19%	-33.98%
Shares Outstanding (Basic)	25	25	25	25	25
Shares Outstanding (Diluted)	25	25	25	25	25
Shares Change (YoY)	-0.00%	-	-	-	-
EPS (Basic)	75.01	46.30	64.60	39.72	24.64
EPS (Diluted)	75.01	46.30	64.60	39.72	24.64
EPS Growth	62.02%	-28.34%	62.67%	61.19%	-33.98%
Free Cash Flow	-167	636.1	171.1	497.7	911.8
Free Cash Flow Per Share	-6.68	25.44	6.84	19.91	36.47
Dividend Per Share	-	32.000	24.000	16.000	10.000
Dividend Growth	-	33.33%	50.00%	60.00%	400.00%
Gross Margin	40.08%	43.55%	53.63%	63.51%	60.66%
Operating Margin	11.37%	12.52%	13.23%	14.84%	8.61%
Profit Margin	8.14%	6.74%	12.47%	9.90%	7.65%
Free Cash Flow Margin	-0.73%	3.71%	1.32%	4.96%	11.32%
EBITDA	2,905	2,484	1,832	1,613	826.7
EBITDA Margin	12.61%	14.47%	14.14%	16.09%	10.26%
D&A For EBITDA	285.8	336.3	117.2	124.7	133.1
EBIT	2,619	2,148	1,714	1,489	693.6
EBIT Margin	11.37%	12.52%	13.23%	14.84%	8.61%
Effective Tax Rate	25.65%	25.98%	26.43%	25.96%	25.82%
Revenue as Reported	23,041	17,569	13,303	10,291	8,204

Source: S&P Global Market Intelligence. Standard template. Financial Sources.